Sunvozertinib Treatment in Untreated Advanced NSCLC With EGFR Uncommon Mutations

Launched by FUDAN UNIVERSITY · Aug 5, 2025

Keywords

ClinConnect Summary

This clinical trial is studying a new treatment called sunvozertinib for people with advanced non-small cell lung cancer (NSCLC) who have specific, less common changes (mutations) in a gene called EGFR. These mutations can affect how the cancer grows. The study aims to see how well sunvozertinib works to shrink tumors and how safe it is for patients who have not yet received any treatment for their advanced cancer.

People who might be eligible to join are adults (18 years or older) with a confirmed diagnosis of a certain type of lung cancer that has these uncommon EGFR mutations. Their cancer must be measurable, meaning doctors can track its size, and they should have a life expectancy of at least 12 weeks. Patients who have had previous cancer treatments or other serious health issues may not qualify. Participants in the trial will receive sunvozertinib and will be closely monitored to understand the treatment’s effects and side effects. This study is currently recruiting patients, so if you or a loved one fits these criteria, talking to your doctor about this option might be helpful.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. ≥18 years old
• • 2. histologically or cytologically confirmed non-squamous NSCLC with documented EGFR uncommon mutations from a local laoratory. at least one EGFR uncommon mutation (excluding EGFR 19del/l858r/T790m/Ex 20ins ) or compund mutations with EGFR uncommon mutations.
• • 3. predicted life expectancy ≥ 12 weeks.
• • 4. patient must have measurable disease according to RECIST 1.1
• Exclusion Criteria:
• • 1. previos systemic anti-tumor therapy
• • 2. a history of malignant tumors within 2years
• • 3. any severa or poorly controlled systemic disease per investigator's judgement
• • 4. active infections